Login to Your Account



Seaside Ends Extension Study, Disappoints Fragile X Patients

By Catherine Shaffer
Staff Writer

Friday, May 24, 2013
Seaside Therapeutics Inc. reluctantly terminated an open-label extension study of STX209 (arbaclofen), for Fragile X syndrome, due to resource limitations. The company said the decision was not related to any safety issues with the drug.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription